New combo therapy aims to shrink tough lung tumors

NCT ID NCT03991819

First seen Jan 10, 2026 · Last updated May 07, 2026 · Updated 20 times

Summary

This early-phase study tests whether adding an experimental drug called binimetinib to the immunotherapy pembrolizumab can help shrink tumors in people with advanced non-small cell lung cancer. About 40 participants with a specific type of lung cancer (PD-L1 high) will receive the combination. The main goals are to find the safest dose and see how well the treatment works.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for NON-SMALL CELL CARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Allan Blair Cancer Centre

    RECRUITING

    Regina, Saskatchewan, S4T 7T1, Canada

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

  • Arthur J.E. Child Comprehensive Cancer Centre

    RECRUITING

    Calgary, Alberta, T2N 4N2, Canada

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

  • Princess Margaret Cancer Centre

    RECRUITING

    Toronto, Ontario, M5G 1Z5, Canada

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

  • Saskatoon Cancer Centre

    RECRUITING

    Saskatoon, Saskatchewan, S7N 4H4, Canada

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

Conditions

Explore the condition pages connected to this study.